By using our site you consent to the CTFN Privacy Policy, Cookies Policy, and Terms of Service.


Four Essentials from CTFN this Week

Linde and Praxair have agreed to offer additional remedies to the U.S. Federal Trade Commission as the industrial gas firms aim to save their $83 billion all-stock merger, CTFN has learned.

Fresenius is on track to close its acquisition of NxStage on the timeline that the parties have indicated to the market, CTFN has learned.

Post trial documents show the FDA’s Form 483 issued August 30 reflects preliminary observations of what the FDA inspectors judged to be “objectionable conditions.” Akorn has until September 21 to submit a response to the FDA and said it will provide its response to both Fresenius and the court.

Under the merger agreement between Bermuda-based Aspen Insurance and Apollo Global Management, the private equity firm agreed to buy the company for $2.6 billion, or $42.75 per share in cash, subject to Aspen not suffering catastrophe losses for the period of July 1, 2018, through January 31, 2019 (or the closing date if it occurs first), of more than $350 million net of reinsurance.

To Keep Reading, Request a Trial
Stephen Velgot

Stephen Velgot

Stephen Velgot has more than twenty years experience as a research analyst. He most recently started an event driven research product at Renaissance Macro Research after covering risk arbitrage at ICAP and event driven situations at Susquehanna and Cathay Financial. Stephen has an MBA in Finance from New York University and a BS in Operations Research from Cornell University.


Interested in a trial?

Simply fill out the form below and one of our representatives will be in touch.